85,111 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Bosun Asset Management LLC

Key Points

• Bosun Asset Management LLC has acquired 85,111 shares of Xeris Biopharma Holdings, valued at approximately $467,000, marking a new position for the firm.
• Several analysts have upgraded Xeris Biopharma's rating to "strong-buy," with a consensus target price of $7.08.
• Insiders sold a total of 192,232 shares of Xeris Biopharma stock in the last three months, indicating a decrease in their holdings.

Bosun Asset Management LLC acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 85,111 shares of the company's stock, valued at approximately $467,000. Bosun Asset Management LLC owned 0.05% of Xeris Biopharma as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nuveen LLC purchased a new position in shares of Xeris Biopharma during the 1st quarter worth about $12,240,000. Invesco Ltd. raised its holdings in shares of Xeris Biopharma by 1,387.8% in the first quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock worth $5,637,000 after buying an additional 957,822 shares during the period. Driehaus Capital Management LLC boosted its holdings in Xeris Biopharma by 137.6% during the 1st quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock valued at $7,749,000 after acquiring an additional 817,525 shares during the period. Cubist Systematic Strategies LLC bought a new position in Xeris Biopharma in the 1st quarter valued at $4,456,000. Finally, Informed Momentum Co LLC increased its stake in Xeris Biopharma by 320.3% in the first quarter. Informed Momentum Co LLC now owns 934,646 shares of the company's stock worth $5,131,000 after purchasing an additional 712,269 shares during the period. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Trading Down 1.9%

Shares of XERS traded down $0.15 during mid-day trading on Tuesday, hitting $7.63. The company's stock had a trading volume of 659,045 shares, compared to its average volume of 2,513,155. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -36.40 and a beta of 0.12. The company's 50-day moving average is $6.25 and its 200-day moving average is $5.18. Xeris Biopharma Holdings, Inc. has a 52-week low of $2.60 and a 52-week high of $8.03.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. As a group, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey W. Sherman sold 42,232 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the transaction, the director owned 219,188 shares in the company, valued at $1,735,968.96. The trade was a 16.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin Mcculloch bought 25,000 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average cost of $4.38 per share, with a total value of $109,500.00. Following the transaction, the insider directly owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 192,232 shares of company stock worth $1,430,777 over the last ninety days. 4.56% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently commented on XERS. HC Wainwright initiated coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They issued a "buy" rating and a $10.00 price target on the stock. Leerink Partners raised their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen lowered Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a report on Friday. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $7.08.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.